Multiple sclerosis is a chronic, inflammatory, autoimmune nervous system disorder where the immune system attacks the protective fat layer called myelin, around the nerve fibers and causes problems with muscle control, vision and other body functions, and affects the spinal cord, and the (CNS) central nervous system, especially the communication between the brain and other areas of the body resulting in loss of balance, coordination and compromised vision.
Multiple sclerosis (MS) is basically an immune-mediated, demyelinating illness which damages the insulating covers of the nerve cells in the brain and spinal cord (CNS). The disease can result in long term disability. It is characterized by inflammation, demyelination, and degenerative changes such as progressive brain and neuroaxonal, loss spinal cord atrophy, among others.
Currently various research studies are taking place in this avenue, which are expected to create a competitive landscape for the Multiple Sclerosis Drugs manufacturers to develop new and innovative treatments, which is expected to create a plethora of opportunities in the multiple sclerosis treatment market. MS, widespread amongst the young adults around the world, is a degenerative neurological condition. On a global scale, an estimated 2.5 million people were diagnosed with MS in 2017, according to the Multiple Sclerosis Trust. MS affects women more than men.
The disease often occurs in the people that are in the age group of 20-40. MS is broadly categorised into four types. These are, relapsing-remitting MS, progressive-relapsing MS, secondary-progressive MS and primary-progressive MS. Relapsing-remitting MS is the most common form of MS that occurs in the patients. It accounts for an approximate 85% of the total MS cases. Approximately 50% of people suffering with relapsing remitting MS go on to develop this form of the disease. Progressive-relapsing MS is rare and comprises of about 5% of the total MS cases. Primary-progressive MS accounts for 10% of the total MS cases. New product launches and significant R&D investment are expected to contribute to the expansion of the market for Multiple Sclerosis drugs.
Investments made in the activities targeted at research and development to boost the market are witnessing great profits in terms of revenue generated from the results of the clinical research and R&D investment. Many pharmaceutical companies across the globe are focusing on developing unorthodox therapies for the treatment of MS. Increased research activities on various novel candidates have also paved the way for many research collaborations between pharmaceutical companies and research institutes, further strengthening the market.
The rising prevalence of the disease has forced governments of many countries to take active measures using recommendations and guidelines. Apart from this, various initiatives to generate awareness around this issue are being launched by government associations to educate patients regarding the different options of treatment available. The growth of multiple sclerosis drugs market is aided by government support as well as help from the various different non-government organizations.
Multiple Sclerosis Drugs Market Value Share Analysis, By Geography (2022)
The report titled “Multiple Sclerosis Drugs Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032” wherein 2021 is historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global multiple sclerosis drugs market. Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market.
Based on Drug Class, the market is segmented into Immunomodulators, Immunosuppressants, Interferons, Others. Based on Route of Administration, the market is segmented into Oral, Injection (Intramuscular, Subcutaneous, Intravenous). Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy. Based on geography, the global multiple sclerosis drugs market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America is sub-segmented into the United States, Canada and Rest of North America. Europe is sub-segmented into Germany, United Kingdom, Belgium, Spain, and Rest of Europe. Asia Pacific is sub-segmented into China, Japan, India, Australia, and Rest of Asia Pacific. Middle East & Africa is sub-segmented into Saudi Arabia, the UAE, and Rest of Middle East & Africa. South America is sub-segmented into Brazil and Rest of South America.
The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment and would identify the segment of the company focusing on multiple sclerosis drugs market. Further, market share of prominent companies in the global multiple sclerosis drugs market would also be estimated. The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, swot analysis, and research and development focus of all the Multiple Sclerosis Drugs companies. The global multiple sclerosis drugs market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution. Product portfolio would focus on all the products under the Multiple Sclerosis Drugs business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global multiple sclerosis drugs market.
The key players in the global multiple sclerosis drugs market include Biogen, Novartis, Roche, Bayer HealthCare, Pfizer, Inc., Merck & Co., Inc., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, Acorda Therapeutics Inc., Actelion Pharmaceuticals (Johnson & Johnson), EMD Serono (Merck KGaA), AbbVie, Inc., Betaseron, CinnoVex, Extavia, Rebif, Tysabr.
The Multiple Sclerosis Drugs Market is Segmented as Follows:
By Drug Class
By Route of Administration
By Distribution Channel
By Region
The base year considered in multiple sclerosis drugs market report is 2022.
The growth of multiple sclerosis drugs market is aided by government support as well as help from the various different non-government organizations.
The global multiple sclerosis drugs market segmented on the basis of drug class, route of administration, distribution channel and geography.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved